Muscle growth may hinge on making more ribosomes

Key Takeaways

• This paper is a review, not a new clinical trial, so it synthesizes evidence rather than proving a new cause-and-effect result.
• Its core claim is that long-term hypertrophy depends on translational capacity, especially ribosome biogenesis, not just short-lived mTORC1 activation.
• The authors argue common RNA measurement methods can underestimate ribosomal gains in growing muscle, which may blur past human findings.
• Age, concurrent endurance training, and training volume may influence how well muscle expands this growth machinery over time.
• For creatine users, the review strengthens the idea that monohydrate is best viewed as a training support tool, not a shortcut around progressive resistance training.
• The practical winner is consistency: enough resistance training stimulus, enough recovery, and enough time for structural adaptation to accumulate.

What the review says is new

The main news from this Cells review is straightforward: the authors argue that brief increases in anabolic signalling are probably not the main limiter of long-term muscle growth. Instead, they make the case that ribosome biogenesis — the process of building new ribosomes, the cellular machinery that translates RNA into protein — may be a key bottleneck for sustained hypertrophy.

That matters because much of the gym conversation around muscle growth still centres on acute pathways such as mTORC1. The review does not say mTORC1 is unimportant. It says acute signalling appears to be permissive, while bigger, lasting growth likely requires a physical expansion of the muscle fibre’s protein-making capacity.

In practical terms, this shifts the emphasis from chasing transient “anabolic spikes” toward creating the training conditions that support months of adaptation. That is highly relevant for people using creatine, because creatine does not directly replace the work of building new translational machinery. Rather, it may help athletes train harder, recover between high-quality efforts, and accumulate the kind of resistance-training stimulus that promotes growth over time. If you are new to supplementation, our creatine guides cover the basics, while a creatine dosage calculator can help with day-to-day intake planning.

The review also highlights a likely reason the literature can look inconsistent: some common lab methods may systematically underestimate ribosomal accretion in actively growing muscle. That is a technical point, but it has real-world importance because it affects how confidently researchers can link molecular changes to visible gains in lean mass and fibre size.

This is a narrative review, not a supplement trial

Readers should be clear on what this paper is and is not. It is a comprehensive review of mechanisms, human evidence, and practical modulators of ribosome biogenesis in skeletal muscle. It is not a randomized trial testing creatine, nor a new intervention study showing that one programme definitively increases ribosome biogenesis more than another.

That design matters for interpretation. Reviews can be very valuable because they bring together scattered mechanistic and human findings into one framework. Here, the framework is that translational capacity may be the real long-term bottleneck to hypertrophy. But a review also depends on the quality and consistency of the underlying evidence, which the authors themselves acknowledge is limited by methodology.

One of the paper’s central critiques is the so-called moving denominator paradox. In simple terms, if muscle tissue is growing and total RNA is used incorrectly as a reference point, researchers may underestimate how much ribosomal content has actually increased. That could make some studies look flatter or noisier than the biology really is.

Other limitations follow from the broader literature: muscle biopsy studies are often small, human training studies can vary widely in volume and duration, and molecular markers do not always map neatly onto visible hypertrophy in the short term. So the paper offers a strong interpretive model, but not the final word. For creatine users, that means this review informs how to think about growth, rather than providing a new creatine-specific dosing rule.

Why this matters if you take creatine

The review never claims creatine directly drives ribosome biogenesis, but it still matters for creatine users because it changes the lens through which supplementation should be judged. If the real barrier to bigger muscles is the gradual expansion of protein-making machinery, then the value of creatine is likely indirect: it helps support the quality and repeatability of training that can build that machinery.

That fits well with the broader evidence base on creatine monohydrate’s safety and efficacy. Creatine is best understood as a performance and training-support supplement, not as a magic anabolic switch. For most healthy adults, the mainstream evidence-based approach remains a loading phase of roughly 20 g/day split into 4 doses for 5-7 days, or simply 3-5 g/day without loading to reach saturation more gradually. Our best creatine rankings and creatine brand reviews can help if you are comparing monohydrate products.

What this review adds is a reminder that the best supplementation plan still sits downstream of good programming. Creatine may let you sustain force output, total work, and training quality. But if hypertrophy depends on long-term structural adaptation inside the muscle cell, then supplements only matter to the extent that they support enough progressive resistance training, enough recovery, and enough time.

That is especially important for frustrated users who expect visible growth from creatine alone. The supplement can help, but it cannot bypass the biology this review is describing.

How this fits with the wider creatine and hypertrophy evidence

Broadly, the review fits rather than conflicts with what sports nutrition researchers already think about creatine and muscle gain. Creatine has long shown the most reliable benefits when paired with resistance training, especially for improving high-intensity exercise capacity and supporting gains in lean mass over time. The present paper provides a useful mechanistic frame for why training quality over months matters so much.

It also aligns with the mainstream point that monohydrate remains the best-studied form. There is no reason to infer from this review that a more exotic creatine form would better influence ribosome biogenesis. If anything, the paper reinforces the importance of fundamentals over marketing. See this review of common creatine questions and misconceptions for the broader consensus on form, safety, and practical use.

The authors also discuss modifiers such as age, concurrent training, and training volume. That is useful context. Older adults may face a harder road to hypertrophy because the machinery that supports adaptation may be less responsive. Concurrent endurance training may sometimes interfere with maximising hypertrophy, depending on how it is programmed. And training volume appears relevant because insufficient volume may not provide enough cumulative stimulus to build translational capacity.

For readers browsing the creatine product catalog, the practical implication is simple: product choice matters less than whether you are consistently doing the work that actually creates the need for more ribosomes in muscle tissue.

Practical takeaways for dosing, timing, and who may benefit most

Nothing in this review changes standard creatine dosing. The most defensible advice remains 3-5 g/day of creatine monohydrate for maintenance, with optional loading if faster saturation matters. Timing is a secondary issue compared with taking it consistently. Daily adherence and a well-built training plan are more important than whether creatine is taken immediately pre- or post-workout.

Where this review does sharpen practice is in programme design. If long-term hypertrophy depends on overcoming a translational-capacity bottleneck, athletes should prioritise:

• Progressive resistance training with enough volume to create a meaningful hypertrophic stimulus.
• Patience, because structural adaptation takes longer than an acute pump or short-lived signalling response.
• Recovery, including adequate protein, calories, and sleep, so the muscle can actually build new tissue.
• Specificity, especially if hypertrophy is the goal and endurance work is also being performed.

Who may care most about this idea? Lifters in a plateau, coaches programming for size, and older adults trying to preserve or regain muscle. In all three cases, the lesson is that creatine may help support the process, but not replace the need for sufficient training stimulus. If your current setup is a scoop of creatine and a loosely structured workout plan, the review suggests your bottleneck is unlikely to be the supplement.

Put differently: once the basics are handled, creatine is useful. Before the basics are handled, creatine is often overrated.

Bottom line

This Cells paper does not prove that ribosome biogenesis is the only driver of muscle growth, and it does not test creatine directly. What it does do is offer a persuasive, evidence-based argument that lasting hypertrophy may depend on building more cellular protein-making machinery, not merely triggering short anabolic signals.

For creatine users, that is a valuable reality check. Creatine monohydrate remains one of the best-supported supplements in sports nutrition, but its real-world payoff likely comes from helping you train in a way that eventually expands muscle’s long-term growth capacity. The supplement is a support act, not the headline biology.

So if you are taking creatine for size, the hierarchy still looks like this:

1. Follow a progressive resistance-training programme.
2. Accumulate enough weekly volume and repeat it for long enough.
3. Eat and recover well enough to support growth.
4. Use creatine monohydrate consistently to help support performance and training output.

That may sound less exciting than claims about instant anabolic pathways, but it is probably closer to the truth. And in hypertrophy, truth tends to beat hype.

Creatine basics that still matter most

• 3-5 g/day Typical maintenance dose — Mainstream evidence-based creatine monohydrate intake.
• ~20 g/day Typical loading intake — Usually split into 4 doses daily.
• 5-7 days Common loading duration — Used to saturate muscle stores faster.
• 1 Best-studied creatine form — Creatine monohydrate remains the reference standard.

Frequently Asked Questions

Sources & Further Reading

• Kreider et al. (2017), ISSN Position Stand: Safety and Efficacy of Creatine — JISSN
• Antonio et al. (2021), Common questions and misconceptions about creatine supplementation — JISSN